Kansenshogaku Zasshi
Online ISSN : 1884-569X
Print ISSN : 0387-5911
ISSN-L : 0387-5911
Comparative Clinical Study of T-2588 and Cefaclor for Chronic Respiratory Tract Infections by a Double-Blind Method
Hiroyuki KOBAYASHI, Shin KAWAI, Akira SAITO, Osamu YAJIMA, Masumi TOMIZAWA, Ichiro NAKAYAMA, Kiyofumi ISHIKAWA, Masao TAMURA, Takashi ITO, Kenichi TAKEUCHI, Yoshikatsu NEMOTO, Issei TANIFUJI, Masami YOSHIDA, Shigeki MORI, Kumi OKABE, Kazutoshi GOMI, Tamotsu TAKISHIMA, Shiroh IDA, Isao OHNO, Kiyoshi KONNO, Kotaro OIZUMI, Akira WATANABE, Seiichi AONUMA, Tsugushi ITO, Izumi HAYASHI, Masataka KATSU, Mieko KAWAI, Takashi INAMATSU, Kyoko URAYAMA, Shinichi OKA, Makiko FUKAYAMA, Junzaburou KABE, Hiroyoshi ISHIBASHI, Kouichirou KUDOU, Fuyuhiko HIGASHI, Yuzo FUNATSU, Hideo IKEMOTO, Kazuyoshi WATANABE, Hiroichi TANIMOTO, Yoshitaka NAKAMORI, Kunihiko YOSHIMURA, Tatsuo NAKATANI, Naohiko CHONABAYASHI, Koichiro NAKATA, Kyoichi TOZUKA, Kihachiro SHIMIZU, Atsushi SAITO, Tadashi MIYAHARA, Keimei MASHIMO, Yoshiji YAMANE, Tatsuo KATO, Kaoru SHIMADA, Shinsaku SAKURAI, Takuo TOYOSHIMA, Kentaro WATANABE, Masaru KOYAMA, Fukuo IIJIMA, Fumio MATSUMOTO, Ippei FUJIMORI, Yoshio KOBAYASHI, Masanori ADACHI, Kazufuto FUKAYA, Takeshi MITSUI, Takao OKUBO, Akira ITO, Shigeki ODAGIRI, Masanori MATSUMURA, Kaneo SUZUKI, Kou MUROHASHI, Hisako SUZUKI, Yasuhiro YOSHIIKE, Mitsuyo KIUCHI, Tsutomu FUKUDA, Masaaki ARAKAWA, Koichi WADA, Osamu SEKINE, Nobuki AOKI, Hajime TAKEDA, Masanaga TAKATOU, Eishi HIGUCHI, Fusanosuke YAMASAKU, Yasutoshi SUZUKI, Kaoru OYAMA, Nobuo OHYA, Mitsuru HAYASE, Shunsuke KITAGAWA, Kaoru SHIMOKATA, Hiroshi AMANO, Saiji YOSHII, Shuzo SAKAI, Tatsuo SATAKE, Kenzoh TAKAGI, Kenichi YAMAKI, Toshihiko TAKEUCHI, Masahito KATO, Joichi KATO, Kunio NANJO, Riichiro MIKAMI, Masayoshi SAWAKI, Keiichi MIKASA, Fumiyuki KUZE, Mitsuru KAWAI, Ryoichi AMITANI, Kokichi YAMAMOTO, Hideki NISHIYAMA, Miki OKAZAKI, Fumio MIKI, Yoshiyasu IKUNO, Eiji INOUE, Minoru YOSHIYAMA, Akihito MURATA, Shinichi TANIZAWA, Kazuo SAKAMOTO, Hirozumi SAKAI, Rinzo SOEJIMA, Hiroshi KAWANE, Yoshihito NIKI, Michifumi ADACHI, Osamu KURIMURA, Tadashi MASUDA, Hideo SASAKI, Hirofumi FUKUHARA, Kouji MOCHIZUKI, Keiko KAWAMURA, Yoshiro SAWAE, Masahide TAKII, Hitoshi NAGANO, Shinichi MATSUO, Atsushi SHINODA, Tsuneo ISHIBASHI, Masahiro TAKAMOTO, Yasuko HARADA, Yoshiya KITAHARA, Masahiro NAKAMURA, Hozumi YAMADA, Osamu KATO, Kohei HARA, Yoshiteru SHIGENO, Hideaki SHIGENO, Yasumasa DOTSU, Masamoto NAKANO, Naomi ITO, Keizo MATSUMOTO, Naoto RIKITOMI, Shukuro ARAKI, Masayuki ANDO, Mineharu SUGIMOTO, Moritaka SUGA, Yasutsugu FUKUDA, Katsumasa TOKUNAGA, Etsuo KINUWAKI, Yasuhiro ETO, Hisato YAMAZAKI, Masaru NASU, Jun GOTO, Yoichiro GOTO, Takayoshi TASHIRO, Kenjiro INOUE, Hirokazu NISHITANI, Kazumine KOBARI, Yuei IRABU, Tsuneo TANAKA, Yasuyuki HAYASHI, Toyoko OGURI
Author information
Keywords: T-2588, Cefaclor, Chronic respiratory tract infection, Comparative study
JOURNAL FREE ACCESS

1986 Volume 60 Issue 9 Pages 1052-1077

Details
Download PDF (3047K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract

The clinical efficacy and safety of T-2588 were compered with those of cefaclor (CCL) in patients with chronic respiratory tract infection by a double-blind study. Administration was performed by oral for a fixed period of 14 days and the daily dosage was fixed at 600 mg for T-2588or 750 mg for CCL.
The following results were obtained.
1) Clinical efficacy rate by committee judgement was 83.6% for T-2588 and 56.3% for CCL, respectively. The statistical analysis of these results revealed that T-2588 was significantly moreeffective than CCL.
2) The results of the clinical efficacy judged by the doctors in charge was similar to efficacy judged by the committee.
3) The bacteriological eradication rate of causative organisms by committee judgement was 77.6% for T-2588 and 52.4% for CCL, respectively. Furthermore, eradication rate of T-2588 in H. influenzae was significantly superior to that of CCL.
4) With respect to the rate of improvement of clinical signs, symptoms and laboratory findings the T-2588 was superior to the CCL in the improvement for cough, sputum volume, sputum property, rale and ESR.
5) The incidence rate of side effect was 4.5% for T-2588 and 6.5% for CCL, respectively, and these were no significant difference between the two drug group. Abnormal laboratory findings were observed at the rate of 15.5% for T-2588 and 5.8% for CCL, respectively. Incidence rate ofabnormal laboratory findings was significantly higher in T-2588 and the most frequent finding was eosinophilia.
6) Usefulness rate judged by committee members for T-2588 and CCL were 80.2% and 55.7%, respectively, and these were significantly different statistically.
7) The results of clinical usefulness judged by the doctors in charge were similar to the usefulness judged by committee. These results indicated that T-2588 is useful drug for the treatment of chronic respiratory tract infections.

Content from these authors
© The Japansese Association for Infectious Diseases
Previous article Next article
Favorites & Alerts

Recently viewed articles
Predecessor

Journal of the Japanese Association for Infectious Diseases

Share this page
feedback
 Top